oral semaglutide clinical trials Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial

In this 68-week randomized clinical trial (just 201 participants), oral # semaglutide provided significantly greater body #weightloss than placebo (estimated treatment difference, –13% ) and improved cardiometabolic risk factors. The safety profile was

28.03

★★★★☆4.8 (126)

Full article: Clinical review of the efficacy and safety of oral semaglutide in patients with type 2 diabetes compared with other oral antihyperglycemic agents and placebo

20.66

★★★★★4.9 (98)

Oral semaglutide 50 mg taken once per day in adults with overweight or obesity (OASIS 1): a randomised, double-blind, placebo-controlled, phase 3 trial

20.68

★★★★★5.0 (157)

Efficacy and safety of once-weekly semaglutide 2·4 mg versus placebo in people with obesity and prediabetes (STEP 10): a randomised, double-blind, placebo-controlled, multicentre phase 3 trial

23.50

★★★★★4.7 (84)

Safety and Pharmacokinetics of Single and Multiple Ascending Doses of the Novel Oral Human GLP-1 Analogue, Oral Semaglutide, in Healthy Subjects and Subjects with Type 2 Diabetes | Clinical Pharmacokinetics

26.56

★★★★★4.9 (203)

Efficacy and safety of oral semaglutide vs sitagliptin in a predominantly Chinese population with type 2 diabetes uncontrolled with metformin: PIONEER 12, a double-blind, Phase IIIa, randomised trial | Diabetologia

27.59

★★★★★5.0 (176)

Efficacy and safety of semaglutide 2.4 mg by race and ethnicity: A post hoc analysis of three randomized controlled trials - Rubino - 2024 - Obesity

22.72

★★★★★4.8 (132)